A typical onset of multiple myeloma manifesting with persistent cytopenias and kidney dysfunction: a case report
DOI:
https://doi.org/10.18203/2320-6012.ijrms20261351Keywords:
Multiple myeloma, Plasma cell discrasia, Cytopenia, Renal impairment, Light chain diseaseAbstract
Multiple myeloma is a clonal plasma cell neoplasm capable of producing severe multisystem compromise, including progressive anemia, renal dysfunction and immune suppression. Its initial presentation is often subtle and nonspecific, delaying diagnosis and treatment. Early recognition is critical to prevent irreversible organ injury. We present the case of a 48-year-old woman with a history of chronic kidney disease who was admitted due to persistent constitutional symptoms, transfusion-dependent anemia, nausea, marked asthenia, weight loss of 8 kilograms and recurrent vomiting. Initial laboratory findings revealed severe cytopenias, elevated creatinine levels and persistent electrolyte imbalance. Autoimmune studies were negative. Serum free light chain testing demonstrated a marked elevation of kappa chains, and bone marrow immunohistochemistry showed strong CD138 positivity in approximately 80 percent of the marrow cellularity, consistent with plasma cell neoplastic infiltration. Flow cytometry confirmed the presence of a clonal plasma cell population compatible with plasma cell dyscrasia. She was diagnosed with active multiple myeloma with renal involvement and severe hematologic compromise, requiring repeated transfusion support and chemotherapy initiation. This case illustrates an atypical and rapidly progressive presentation of multiple myeloma in a relatively young patient, initially masked by chronic kidney disease and constitutional symptoms. Persistent cytopenias combined with renal impairment should prompt early investigation for plasma cell disorders, as timely diagnosis remains essential to reduce morbidity and improve prognosis.
Metrics
References
Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(10):1336-55. DOI: https://doi.org/10.1002/ajh.26590
Rajkumar SV. International Myeloma Working Group. Updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538-48. DOI: https://doi.org/10.1016/S1470-2045(14)70442-5
Rajkumar SV. Evolving diagnostic criteria for multiple myeloma. Hematology Am Soc Hematol Educ Program. 2015;(1):272-8. DOI: https://doi.org/10.1182/asheducation-2015.1.272
Leung N, Rajkumar SV, Kyle RA, Dispenzieri A, Kapoor P. Multiple myeloma with acute light chain cast nephropathy. Blood Cancer J. 2023;13:145. DOI: https://doi.org/10.1038/s41408-023-00806-w
Tyszkiewicz A, Heras Benito M, Urzola Rodríguez G, Rey Búa B, Baile González M, Sánchez-Jáuregui Castillo M. Multiple myeloma with chronic kidney disease dependent on dialysis: case presentation and review. Nefrología. 2022;42(5):604-10. DOI: https://doi.org/10.1016/j.nefroe.2022.03.002
Sridevi HB. Pancytopenia in multiple myeloma – an enigma: our experience from tertiary care hospital. J Clin Diagn Res. 2015;9(9):OD05-8. DOI: https://doi.org/10.7860/JCDR/2015/12788.6718
Nightingale B, Decker M, Ryan R, Kaczmarczyk K, Jandir P, Waykole T, et al. Multiple Myeloma: A Review of the Literature and a Case Report. World J Oncol. 2024;15(2):34-45. DOI: https://doi.org/10.14740/wjon1780
Hussain M, Yellapragada S, Al Hadidi S. A Review Article: Multiple myeloma and related plasma cell disorders. Hemato Oncol. 2023;17(4):31-42.
Patel S. Myeloma presenting with pancytopenia: our experience. J Clin Haematol. 2025;12(4):256-62.
Rattu MA. Spotlight on multiple myeloma treatment and pharmacist support. US Pharmacist. 2025;50(5):44-52.
Savuliak HR, Bardash VO, Maksymets TA, Perepelytsya MV, Kit ZM, Karpyshyn NV, et al. Clinical and laboratory correlates of kidney function in multiple myeloma patients. Wiad Lek. 2025;78(6):1019-25. DOI: https://doi.org/10.36740/WLek/207359
Zanwar S, Ho M, Lin Y, Kapoor P, Binder M, Buadi FK, et al. Current risk stratification and staging of multiple myeloma: an evolving paradigm. Leukemia. 2025;39(4). DOI: https://doi.org/10.1038/s41375-025-02654-y
Fava A, Fulladosa X, Montero N, Draibe J, Goma M, Cruzado JM. Treatment of multiple myeloma with renal involvement: the nephrologist’s view. Clin Kidney J. 2018;11(2):195-208. DOI: https://doi.org/10.1093/ckj/sfy065
Kyle RA, Rajkumar SV, Durie BGM, Ludwig H, Lonial S, Kumar SK, et al. Diagnostic criteria, staging, risk stratification and response assessment of multiple myeloma. Leukemia. 2009;23(1):3-9. DOI: https://doi.org/10.1038/leu.2008.291
International Myeloma Working Group. IMWG recommendations: renal impairment in multiple myeloma. IMWG Resource Library. 2023.